Inclusion Criteria for Liver Metastasis from Colorectal Cancer Clinical Trial

Patients with confirmed liver metastasis from colon cancer diagnosed by organization or cellular pathology.\
Patients who have previously received first-line chemotherapy and have achieved disease control (PR+SD) according to RECIST 1.1 evaluation.\
Patients with liver metastasis from colorectal cancer who have undergone curative local treatment (surgery, ablation, SBRT) and achieved no evidence of disease (NED). NED is defined as: a. No residual tumor or tumor activity in the primary or metastatic lesions as seen on CT, MRI, PET-CT after local treatment. b. No cancer cells detected in the biopsy of suspicious lesions.\
Patients who have completed routine adjuvant chemotherapy after achieving NED (such as 4-8 cycles of Xelox regimen, 6-12 cycles of FOLFOX regimen, or completion of fluoropyrimidine monotherapy without receiving adjuvant chemotherapy in the recent past), and disease progression is not observed.\
The time interval between the last chemotherapy and enrollment does not exceed 2 months.\
Performance Status (ECOG) score \u003c= 2.\
Age between 18 and 75 years old (including 18 and 75 years old).\
Hematology: WBC \u003e 3\u00d7109 /L; PLT \u003e 80\u00d7109 /L; Hb \u003e 90g/L.\
Liver function: ALT and AST \u003c= 2.5\u00d7ULN; bilirubin \u003c= 1.5\u00d7ULN.\
Renal function: Serum creatinine \u003c= 1.5\u00d7ULN or creatinine clearance rate (CCr) \u003e= 60ml/min.\
Signed informed consent, willingness to undergo treatment according to this protocol, ability to adhere to medication, and good compliance.